[
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 2,
    "category": "Parties"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 5,
    "category": "Expiration Date"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 8,
    "category": "Governing Law"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 11,
    "category": "Exclusivity"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 16,
    "category": "Rofr/Rofo/Rofn"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 18,
    "category": "Anti-Assignment"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 19,
    "category": "Revenue/Profit Sharing"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 25,
    "category": "License Grant"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 26,
    "category": "Non-Transferable License"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 28,
    "category": "Affiliate License-Licensor"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 27,
    "category": "Affiliate License-Licensee"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 32,
    "category": "Post-Termination Services"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 33,
    "category": "Audit Rights"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 34,
    "category": "Uncapped Liability"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 35,
    "category": "Cap On Liability"
  },
  {
    "text": "AGREEMENT",
    "bbox": [
      613,
      72,
      720,
      84
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "This Agreement (the \"Agreement') is made and entered into as of August 21, 2018 (the \"Effective Date'), by and between Pfizer Inc",
    "bbox": [
      190,
      88,
      1000,
      101
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "(\"Pfizer'), a Delaware corporation, with a principal place of business at 235 East 42nd Street, New York, New York 10017 and Exact Sciences.",
    "bbox": [
      124,
      104,
      1000,
      117
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Corporation (\"Exact'), a Delaware corporation with a principal place of business at 441 Charmany Drive, Madison, Wisconsin 53719. Pfizer and",
    "bbox": [
      123,
      120,
      1000,
      133
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Exact may each be referred to herein individually as a \"Party\"' and collectively as the \"Parties\"'.",
    "bbox": [
      123,
      137,
      838,
      149
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Exact has marketing and proprietary rights to the Product (as defined below) in the United States;",
    "bbox": [
      191,
      152,
      1000,
      165
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Pfizer has sales, marketing, analytical, and other core capabilities and competencies to promote and market branded",
    "bbox": [
      190,
      167,
      1000,
      182
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "prescription products; and",
    "bbox": [
      122,
      184,
      325,
      197
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "WHEREAS, Exact desires to work with Pfizer to leverage Pfizer's expertise in sales, marketing, analytical, and other core capabilities and.",
    "bbox": [
      191,
      201,
      1000,
      213
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "competencies for the Product in the United States and Pfizer desires to provide such expertise, including through its Sales Representatives, and to",
    "bbox": [
      122,
      217,
      1000,
      229
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "invest in Exact's Promotion of the Product in the United States.",
    "bbox": [
      123,
      233,
      593,
      244
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration,.",
    "bbox": [
      189,
      248,
      1000,
      261
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:",
    "bbox": [
      123,
      265,
      852,
      277
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.DEFINITIONS.",
    "bbox": [
      113,
      281,
      242,
      292
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.1\"AdvaMed Code\"' shall have the meaning set forth in Section 3.2(c)(ii).",
    "bbox": [
      191,
      297,
      736,
      309
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.2\"Advertising\" shall mean the paid advertising, planning, purchasing and placement of advertising for a prescription medical device",
    "bbox": [
      189,
      312,
      1000,
      326
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "subject to pre-market approval in the Territory through any means, including television, print, radio/audio, in-office/placed-",
    "bbox": [
      259,
      329,
      1000,
      341
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "based, digital, web, search (SEM/SEO), social media, mobile and any and all new and emerging media channels for consumers,",
    "bbox": [
      258,
      345,
      1000,
      357
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "healthcare institutions and healthcare providers..",
    "bbox": [
      258,
      360,
      623,
      373
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.3\"Affiliate(s)\"' shall mean, with respect to any Party, any other Person which controls, is controlled by or is under common control",
    "bbox": [
      191,
      376,
      1000,
      388
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "with such Party. A Person shall be regarded as in control of another Person if it owns or controls at least fifty percent (50%) of",
    "bbox": [
      258,
      393,
      1000,
      405
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "the equity securities of such other Person entitled to vote in the election of directors (or, in the case of an entity that is not a",
    "bbox": [
      259,
      409,
      1000,
      421
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "corporation, for the election of the corresponding managing authority); provided, however, that the term \"Affiliate\" shall not",
    "bbox": [
      258,
      425,
      1000,
      437
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "include subsidiaries or other entities in which a Party or its Affiliates owns a majority of the ordinary voting power necessary to",
    "bbox": [
      258,
      441,
      1000,
      453
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "elect a majority of the board of directors or other governing board, but is restricted from electing such majority by contract or",
    "bbox": [
      258,
      456,
      1000,
      469
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "otherwise, until such time as such restrictions are no longer in effect.",
    "bbox": [
      258,
      473,
      774,
      484
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1.4\"Agreement\"' shall have the meaning set forth in the preamble.",
    "bbox": [
      192,
      489,
      686,
      501
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "1",
    "bbox": [
      661,
      506,
      671,
      515
    ],
    "label": 38,
    "category": "Insurance"
  },
  {
    "text": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018",
    "bbox": [
      133,
      1000,
      518,
      1000
    ],
    "label": 38,
    "category": "Insurance"
  }
]